Usana Health Sciences Inc (USNA) SEC Filing 10-Q Quarterly report for the period ending Saturday, March 28, 2020

SEC Filings

USNA Quarterly Reports

Usana Health Sciences Inc

CIK: 896264 Ticker: USNA
Exhibit 99.1

USANA Health Sciences Reports First Quarter Results

SALT LAKE CITY--(BUSINESS WIRE)--April 21, 2020--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended March 28, 2020.

Key Financial & Operating Highlights

  • Global manufacturing and distribution remain fully operational.
  • Continued consumer demand and a successful promotion combine to generate $266.6 million in net sales during the quarter.
  • Company is following guidelines from government and health officials, to keep employees safe, including a work-from-home strategy for most employees and additional safety precautions for manufacturing and distribution employees.
  • Associates pivot to continue holding meetings and selling virtually/on-line.
  • Updated 2020 outlook reflects impact of a stronger U.S. dollar and continued uncertainty surrounding COVID-19.

Q1 2020 Financial Performance

Consolidated Results

Net Sales

$266.6 million

  • -2.3% vs. prior-year quarter
  • +0.1% constant currency vs. prior-year quarter
  • -$6.6 million fx impact, or -2.4%

Diluted EPS


  • +21.8% vs. prior-year quarter
  • Diluted shares of 21.6 million, -9.9%

Active Customers


  • -2.2% vs. prior-year quarter

Cash & Cash Equivalents

$194.1 million


The following information was filed by Usana Health Sciences Inc (USNA) on Tuesday, April 21, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Usana Health Sciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Usana Health Sciences Inc.


Assess how Usana Health Sciences Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Usana Health Sciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools


Learn More
Bullish Bearish Neutral
Filter Sentiment:
Filter Category:
Filter Subcategory:
Cash Flow
Inside Usana Health Sciences Inc's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statement Of Stockholders' Equity
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Income
Common Stock And Earnings Per Share
Common Stock And Earnings Per Share (Narrative) (Details)
Common Stock And Earnings Per Share (Schedule Of Earnings Per Share) (Details)
Common Stock And Earnings Per Share (Schedule Of Shares Not Included In The Computation Of Diluted Eps) (Details)
Common Stock And Earnings Per Share (Tables)
Derivative Financial Instruments
Derivative Financial Instruments (Narrative) (Details)
Fair Value Measures
Fair Value Measures (Narrative) (Details)
Fair Value Measures (Schedule Of Assets And Liabilities Measured At Fair Value) (Details)
Fair Value Measures (Tables)
Inventories (Schedule Of Inventories) (Details)
Inventories (Tables)
Line Of Credit
Line Of Credit (Narrative) (Details)
Organization, Consolidation, And Basis Of Presentation
Organization, Consolidation, And Basis Of Presentation (Narrative) (Details)
Organization, Consolidation, And Basis Of Presentation (Policy)
Revenue And Contract Liabilities
Revenue And Contract Liabilities (Narrative) (Details)
Revenue And Contract Liabilities (Schedule Of Contract Liabilities From Contract With Customers) (Details)
Revenue And Contract Liabilities (Tables)
Segment Information
Segment Information (Consolidated Net Sales And Long Lived Assets) (Details)
Segment Information (Narrative) (Details)
Segment Information (Schedule Of Revenue Percentage By Product) (Details)
Segment Information (Schedule Of Revenues From External Customers By Geographical Areas) (Details)
Segment Information (Tables)

Material Contracts, Statements, Certifications & more

Usana Health Sciences Inc provided additional information to their SEC Filing as exhibits

Ticker: USNA
CIK: 896264
Form Type: 10-Q Quarterly Report
Accession Number: 0001562762-20-000164
Submitted to the SEC: Tue May 05 2020 2:22:51 PM EST
Accepted by the SEC: Tue May 05 2020
Period: Saturday, March 28, 2020
Industry: Medicinal Chemicals And Botanical Products

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: